Orchid Pharma Ltd - 524372 - Sub: Notice Of Termination - Rule 144A And Regulation S Global Depositary Receipt Facilities
Sub: Notice of termination - Rule 144A and Regulation S Global Depositary Receipt Facilities21-10-2021
21-10-2021
Orchid Pharma Ltd - 524372 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 032320 Name of the Signatory :- NIKITA KDesignation :- Company Secretary and Compliance Officer20-10-2021
Orchid Pharma Ltd - 524372 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 06, 2021 for Dhanuka Laboratories Ltd08-10-2021
Orchid Pharma Ltd - 524372 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI(DP) Regulations,2018 for the quarter ended September 30,202106-10-2021
Orchid Pharma Ltd - 524372 - Closure of Trading Window
Intimation for closure of Trading window in terms of SEBI (Prohibition of Insider Trading) Regulations, 201530-09-2021
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Credit Rating
Intimation under Regulation 30 (6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015- Revision/Assignment of credit rating for bank facilities30-09-2021
Orchid Pharma Ltd - 524372 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
intimation under Regulation 39(3) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015-Loss of share certificate-Reg.29-09-2021
Orchid Pharma Ltd - 524372 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Termination of the Deposit agreements in respect of the Global Depository Receipts ('GDRs') of the Company25-09-2021
Orchid transfers formulations business to OrBion Pharma
Transfers its operating formulations unit Irungattukottaifor a lumpsum consideration of up to 170 crore19-09-2021
Orchid transfers formulations business to OrBion Pharma
Transfers its operating formulations unit Irungattukottaifor a lumpsum consideration of up to 170 crore18-09-2021